ACE2 and COVID-19: Other possible disadvantages of the use of propofol in COVID-19 patients include the occurrence of hyperlipidemia, which has been associated with an increased risk of mechanical failure of the extracorporeal circuit [15, 39], as well as an increased expression of angiotensin-converting enzyme 2 (ACE-2) in human pulmonary vessels [40].